Invited commentary  by Huber, Thomas S.
110. Raftery J. NICE: faster access to modern treatments? Analysis of
guidance on health technologies. BMJ 2001;323:1300-3.
111. Garber AM, Phelps CE. Economic foundations of cost-effectiveness
analysis. J Health Econ 1997;16:1-31.
112. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of
cost-effectiveness analysis in health-care resource allocation decision-
making: how are cost-effectiveness thresholds expected to emerge?
Value Health 2004;7:518-28.
113. Ekman M. Studies in health economics: Stockholm: EFI, Stockholm
School of Economics, 2002.
114. Greenhalgh RM, Brown LC, Kwong GP, Powell JT, Thompson SG.
Comparison of endovascular aneurysm repair with open repair in
patients with abdominal aortic aneurysm (EVAR trial 1), 30-day
operative mortality results: randomised controlled trial. Lancet
2004;364:843-8.
115. Angle N, Dorafshar AH,MooreWS, Quinones-BaldrichWJ, Gelabert
HA, Ahn SS, et al. Open versus endovascular repair of abdominal
aortic aneurysms: what does each really cost? Ann Vasc Surg 2004;18:
612-8.
116. Wilmink AB, Quick CR, Hubbard CS, Day NE. Effectiveness and cost
of screening for abdominal aortic aneurysm: results of a population
screening program. J Vasc Surg 2003;38:72-7.
Submitted Nov 3, 2004; accepted Jan 30, 2005.
INVITED COMMENTARY
Thomas S. Huber, MD, PhD, Gainesville, Fla
The authors have developed a Markov decision analysis model
to examine the cost-effectiveness of different ultrasound scanning–
based screening strategies for abdominal aortic aneurysms (AAAs)
inmen. The various assumptions incorporated into themodel were
supported by an extensive systematic review of the literature and
were appropriately tested by using multiple sensitivity analyses.
Although the utility of the model and the validity of the results are
contingent on the accuracy of these assumptions, it seems that the
authors were both thoughtful and thorough in their approach. The
authors reported that the cost per life-year saved was $10,474 for a
65-year-old man screened once, with a range from $8309 to
$14,084 for the various other strategies, including patients with
popliteal artery aneurysms and those who had a sibling with an
AAA. Notably, screening resulted in only modest 0.1- and 0.6-year
increases in the mean life expectancies among all the patients
screened and the subset of those with an AAA, respectively. The
risk of aneurysm rupture and long-term survival had the most
dramatic effect on the cost-effectiveness of the screening strategies
in the sensitivity analyses. The results of the model were validated
by comparison with several large clinical trials that examined both
the screening and treatment of AAAs, although this validation was
not completely surprising because several of these definitive trials
were incorporated into the model assumptions. The cost per
quality-adjusted life-year saved for the aneurysm screening was well
below the frequently quoted $50,000/quality-adjusted life-year
threshold and was below the values reported for cervical cancer,
breast cancer, and hypertension screening, as reported by the
authors. Unfortunately, the authors’ conclusions that “screening
for AAA may be cost-effective in 65-year-old men, while screening
60-year-oldmenwith a re-screening could be equally cost-effective
with the advantage of more LYG (life years gained)” were not
definitive. The authors state that additional studies are necessary
before the preferred screening strategy can be identified. It is
important to note that all the AAA repairs in the model were
performed by using the open surgical technique. Although this
simplifies the analyses, it potentially limits the impact of the study,
given the expanding applications of the endovascular technique. It
is conceivable that the lower perioperative mortality rate associated
with the endovascular approach may offset the increased device-
and surveillance-related costs, as suggested by the authors.
The findings in this study further justify screening for AAA in
elderly men and demonstrate its cost-effectiveness. During the
review process of the authors’ manuscript, the United States Pre-
ventative Task Force issued a report recommending a single
screening ultrasound scan for AAA in men 65 to 75 years of age
who have a smoking history. The Preventative Task Force stated
that the literature did not substantiate AAA screening for women,
even among those with a family history of AAA, and stated that the
harms of screening outweighed the risks. Despite the strength of
the evidence supporting screening and the Preventative Task Force
recommendations, several challenges must be overcome before
screening becomes a routine clinical practice. We, as a collective
group of health-care providers that deal with patients with AAA,
must educate our primary care and cardiology colleagues. Further-
more, we must lobby our respective lawmakers in support of the
pending screening legislation initiated by the National Aneurysm
Alliance and the Society of Vascular Surgery. Finally, we must
initiate the appropriate clinical trials to resolve the outstanding
issues highlighted by the authors and the Preventative Task Force.
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